Renée Simon1, Jean Latreille2, Claire Matte1, Pierre Desjardins3, Eric Bergeron4. 1. The Department of Surgery, Hôpital Charles LeMoyne, Greenfield Park, and the Centre Intégré de Cancérologie, Montérégie, Que. 2. The Department of Oncology, Hôpital Charles LeMoyne, Greenfield Park, and the Centre Intégré de Cancérologie, Montérégie, Que. 3. The Department of Oncology, Hôpital Charles LeMoyne, Greenfield Park, Que., Centre Intégré de Cancérologie, Montérégie, Que. 4. The Department of Surgery, Hôpital Charles LeMoyne, Greenfield Park, Que.
Abstract
BACKGROUND: Adjuvant hormonal therapy is crucial in the treatment of estrogen receptor-positive breast cancer. The nonadherence rate to hormonal treatment is reported to be as high as 60%. The goal of this study was to evaluate the factors evoked by the patients as well as the demographic and disease-related factors that could be associated with nonadherence to adjuvant hormonal therapy. METHODS: All consecutive patients treated for an estrogen receptor-positive breast cancer who showed up for regular follow-up with a single breast specialist between November 2008 and April 2009 were included in the study. We assessed adherence to hormonal therapy (either with tamoxifen or aromatase inhibitor). Reasons for adherence and nonadherence were collected. Records were also reviewed for demographic and cancer characteristics and for treatment components. RESULTS: We included 161 patients in the study; 150 (93.2%) adhered to hormonal treatment. Side effects and absence of conviction were the main reasons for nonadherence. The importance of the diagnosis of cancer, fear of recurrence and regular follow-up were reported as the main reasons for adherence. CONCLUSION: Severity of disease and side effects are associated with nonadherence to treatment. Strict follow-up appears to be a necessary adjunct in the adherence to treatment. The association between demographic and cancer characteristics and treatment components needs further investigation. However, these factors may help identify patients at risk of nonadherence and help the oncology team.
BACKGROUND: Adjuvant hormonal therapy is crucial in the treatment of estrogen receptor-positive breast cancer. The nonadherence rate to hormonal treatment is reported to be as high as 60%. The goal of this study was to evaluate the factors evoked by the patients as well as the demographic and disease-related factors that could be associated with nonadherence to adjuvant hormonal therapy. METHODS: All consecutive patients treated for an estrogen receptor-positive breast cancer who showed up for regular follow-up with a single breast specialist between November 2008 and April 2009 were included in the study. We assessed adherence to hormonal therapy (either with tamoxifen or aromatase inhibitor). Reasons for adherence and nonadherence were collected. Records were also reviewed for demographic and cancer characteristics and for treatment components. RESULTS: We included 161 patients in the study; 150 (93.2%) adhered to hormonal treatment. Side effects and absence of conviction were the main reasons for nonadherence. The importance of the diagnosis of cancer, fear of recurrence and regular follow-up were reported as the main reasons for adherence. CONCLUSION: Severity of disease and side effects are associated with nonadherence to treatment. Strict follow-up appears to be a necessary adjunct in the adherence to treatment. The association between demographic and cancer characteristics and treatment components needs further investigation. However, these factors may help identify patients at risk of nonadherence and help the oncology team.
Authors: Rebecca A Silliman; Edward Guadagnoli; William Rakowski; Mary Beth Landrum; Timothy L Lash; Robert Wolf; Aliza Fink; Patricia A Ganz; Jerry Gurwitz; Catherine Borbas; Vincent Mor Journal: J Clin Oncol Date: 2002-06-01 Impact factor: 44.544
Authors: Bernard Fisher; John Bryant; James J Dignam; D Lawrence Wickerham; Eleftherios P Mamounas; Edwin R Fisher; Richard G Margolese; Lois Nesbitt; Soonmyung Paik; Thomas M Pisansky; Norman Wolmark Journal: J Clin Oncol Date: 2002-10-15 Impact factor: 44.544
Authors: Paul E Goss; James N Ingle; Silvana Martino; Nicholas J Robert; Hyman B Muss; Martine J Piccart; Monica Castiglione; Dongsheng Tu; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; Patrick Therasse; Michael J Palmer; Joseph L Pater Journal: N Engl J Med Date: 2003-10-09 Impact factor: 91.245
Authors: Gretchen Kimmick; Sara N Edmond; Hayden B Bosworth; Jeffrey Peppercorn; Paul K Marcom; Kimberly Blackwell; Francis J Keefe; Rebecca A Shelby Journal: Breast Date: 2015-07-16 Impact factor: 4.380
Authors: Joseph A Greer; Nicole Amoyal; Lauren Nisotel; Joel N Fishbein; James MacDonald; Jamie Stagl; Inga Lennes; Jennifer S Temel; Steven A Safren; William F Pirl Journal: Oncologist Date: 2016-02-26
Authors: Caitriona Cahir; Stephan U Dombrowski; Catherine M Kelly; M John Kennedy; Kathleen Bennett; Linda Sharp Journal: Support Care Cancer Date: 2015-03-07 Impact factor: 3.603
Authors: Ilana Graetz; Caitlin N McKillop; Edward Stepanski; Gregory A Vidal; Janeane N Anderson; Lee S Schwartzberg Journal: J Cancer Surviv Date: 2018-02-28 Impact factor: 4.442
Authors: Laura C Pinheiro; Stephanie B Wheeler; Katherine E Reeder-Hayes; Cleo A Samuel; Andrew F Olshan; Bryce B Reeve Journal: J Oncol Pract Date: 2017-03-14 Impact factor: 3.840
Authors: Ekim Ekinci; Salima Nathoo; Thushara Korattyil; Aisha Vadhariya; Hanna A Zaghloul; Polly A Niravath; Susan M Abughosh; Meghana V Trivedi Journal: J Cancer Surviv Date: 2018-02-02 Impact factor: 4.442
Authors: Miryam Yusufov; Margo Nathan; Aleta Wiley; Julia Russell; Ann Partridge; Hadine Joffe Journal: Breast Cancer Res Treat Date: 2020-09-12 Impact factor: 4.872